Point72 Asset Management
CAPR icon

Point72 Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Point72 Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$949K – 2218
2025
Q1 		$949K Buy
+100,000
New +$1.39M ﹤0.01% 1466

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management's CAPR Position: Q1 2026 in Review

Point72 Asset Management reduced its Capricor Therapeutics (CAPR) stake by 55% in Q1 2026, selling an estimated $27.1M and leaving 821,179 shares worth $25M. The position accounts for 0.03% of the portfolio, ranked #691.

Point72 Asset Management first reported a position in CAPR in Q3 2024 and has held it in 4 quarters since. The position peaked at $53.1M in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • Point72 Asset Management held 821,179 shares of Capricor Therapeutics worth $25M as of Q1 2026.
  • Point72 Asset Management sold 1,018,697 Capricor Therapeutics shares in Q1 2026, an estimated $27.1M.
  • Capricor Therapeutics made up 0.03% of Point72 Asset Management's portfolio in Q1 2026, its #691 holding.
  • Point72 Asset Management first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Point72 Asset Management's Capricor Therapeutics position peaked at $53.1M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.